Trial Profile

A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine; Lopinavir/ritonavir; Stavudine; Tenofovir disoproxil fumarate
Indications HIV infections; HIV-1 infections
Focus Therapeutic Use

21 May 2012 Biomarkers information updated
01 Apr 2010 Results of once- vs twice-daily therapy published in Clinical Infectious Diseases.
13 Jul 2009 Results published in Archives of Internal Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com